# Airna Corporation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/airna

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.airna.com
- Total disclosed funding: $215M
- Latest round: Series B (Apr 1, 2025)
- Investors on record: 8

## About

Based in Massachusett, US, and founded in 2021,  Airna Corporation operates as biotechnology research, which provides the next generation of RNA editing therapeutics. As of 2023, the firm is headed by its CEO Kris Elverum. In July 2024, AIRNA Corporation, Inc. raised USD 60 million in series A funding led by Forbion, with participation from ARCH Venture Partners, +ND Capital, Ono Venture Investment, Alexandria Venture Investments, and other unspecified investors also participated in the round. In April 2025,  Airna Corporation raised USD 155 million in series B funding co-led by new investor Venrock Healthcare Capital Partners and returning investor Forbion, with participation from other returning investors ARCH Venture Partners and +ND Capital. New investors Nextech, RTW Investments, and other unspecified investors also participated in the round. The company offers an RNA editing platform to help patients with both common and unusual disorders regain their health. The company's RESTORE+™ platform, which develops genetic medications for both common and rare disorders, aims to restore a patient's health. A methodical development of the first released ADAR platform is RESTORE+™. The company plans to use the April 2025 funding to support its research and development in treatment for patients with lung and liver disease.

## Funding rounds

- Series B, Apr 1, 2025, $155M — ARCH Venture Partners, Forbion, +ND Capital, Nextech, RTW Investments, Venrock Healthcare Capital Partners
- Series A, Jul 31, 2024, $60M — ARCH Venture Partners, Alexandria Venture Investments, Forbion, +ND Capital, Ono Venture Investment

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A, Series B
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A
- Forbion (https://capitalatlas.ai/funds/forbion) — Series A, Series B
- +ND Capital (https://capitalatlas.ai/funds/nd-capital) — Series A, Series B
- Ono Venture Investment (https://capitalatlas.ai/funds/ono-venture-investment) — Series A
- Nextech (https://capitalatlas.ai/funds/nextech) — Series B
- RTW Investments (https://capitalatlas.ai/funds/rtw-investments) — Series B
- Venrock Healthcare Capital Partners (https://capitalatlas.ai/funds/venrock-healthcare-capital-partners) — Series B